HRP20020045A2 - Oral liquid compositions - Google Patents
Oral liquid compositionsInfo
- Publication number
- HRP20020045A2 HRP20020045A2 HR20020045A HRP20020045A HRP20020045A2 HR P20020045 A2 HRP20020045 A2 HR P20020045A2 HR 20020045 A HR20020045 A HR 20020045A HR P20020045 A HRP20020045 A HR P20020045A HR P20020045 A2 HRP20020045 A2 HR P20020045A2
- Authority
- HR
- Croatia
- Prior art keywords
- oral liquid
- liquid compositions
- pharmaceutical compositions
- preparation
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/354,982 US6365180B1 (en) | 1998-01-20 | 1999-07-16 | Oral liquid compositions |
PCT/US2000/019372 WO2001013897A1 (fr) | 1999-07-16 | 2000-07-14 | Compositions buvables |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20020045A2 true HRP20020045A2 (en) | 2006-06-30 |
Family
ID=23395748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020045A HRP20020045A2 (en) | 1999-07-16 | 2002-01-17 | Oral liquid compositions |
Country Status (18)
Country | Link |
---|---|
US (1) | US6365180B1 (fr) |
EP (1) | EP1196147A4 (fr) |
JP (1) | JP2003507415A (fr) |
KR (1) | KR20020050223A (fr) |
CN (1) | CN1407887A (fr) |
AU (1) | AU770772B2 (fr) |
BR (1) | BR0012488A (fr) |
CA (1) | CA2376180A1 (fr) |
CZ (1) | CZ2002129A3 (fr) |
HR (1) | HRP20020045A2 (fr) |
MX (1) | MXPA02000583A (fr) |
NO (1) | NO20020208L (fr) |
RU (1) | RU2252019C2 (fr) |
SI (1) | SI20849A (fr) |
SK (1) | SK572002A3 (fr) |
UA (1) | UA80085C2 (fr) |
WO (1) | WO2001013897A1 (fr) |
ZA (1) | ZA200200741B (fr) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6602467B1 (en) * | 1998-07-24 | 2003-08-05 | Therox, Inc. | Apparatus and method for blood oxygenation |
CA2406383A1 (fr) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Agents de reduction de a.beta.42 |
JP4865958B2 (ja) * | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
US7855082B1 (en) | 2001-10-31 | 2010-12-21 | Astrazeneca Ab | Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole |
US20040006109A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of non-enterically coated acid-labile drugs |
WO2004028456A2 (fr) * | 2002-09-26 | 2004-04-08 | Myriad Genetics, Inc | Procede et composition pour traiter des troubles neurodegeneratifs |
ITMI20022777A1 (it) * | 2002-12-27 | 2004-06-28 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento. |
EP1603548A4 (fr) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Composition et methode de traitement de troubles neurodegeneratifs |
JP2006518751A (ja) * | 2003-02-20 | 2006-08-17 | サンタラス インコーポレイティッド | 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物 |
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US20050042284A1 (en) * | 2003-07-11 | 2005-02-24 | Myriad Genetics, Incorporated | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
US20050031700A1 (en) * | 2003-07-18 | 2005-02-10 | Sanatarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CA2531564C (fr) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Formulations pharmaceutiques utilisees pour inhiber une secretion acide et procede de fabrication associe |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
CA2554271A1 (fr) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combinaison d'un inhibiteur de la pompe a protons, d'un tampon et d'un medicament anti-inflammatoire non steroidien |
US20050203115A1 (en) * | 2004-03-10 | 2005-09-15 | Sancilio Frederick D. | Narcotic-NSAID ion pairs |
WO2006001877A2 (fr) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs |
CA2561700A1 (fr) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique |
CN1946906A (zh) * | 2004-04-29 | 2007-04-11 | 吉斯通护岸系统股份有限公司 | 用于墙、护墙和类似物的饰面 |
US8906940B2 (en) * | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
ITMI20041245A1 (it) * | 2004-06-22 | 2004-09-22 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
WO2006020850A2 (fr) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs |
CA2618985A1 (fr) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs |
WO2006020852A2 (fr) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs |
US20060088590A1 (en) * | 2004-10-22 | 2006-04-27 | Banner Pharmacaps, Inc. | Non-blooming gelatin and non-gelatin formulations |
WO2006052922A2 (fr) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Formulations pharmaceutiques de cyclodextrines et composes modulateurs du recepteur d'oestrogenes selectifs |
WO2006052921A2 (fr) * | 2004-11-08 | 2006-05-18 | Eastman Chemical Company | Agents de solubilisation de la cyclodextrine pour des formulations liquides et semi-solides |
US20070053868A1 (en) | 2005-03-08 | 2007-03-08 | Banner Pharmacaps, Inc. | Solvent system for enhancing the solubility of pharmaceutical agents |
EP1903039A4 (fr) * | 2005-06-13 | 2010-09-22 | Takeda Pharmaceutical | Produit d injection |
WO2006138534A2 (fr) * | 2005-06-15 | 2006-12-28 | Morton Grove Pharmaceuticals, Inc. | Formulation liquide stable de la warfarine sodique et procede de fabrication de celle-ci |
JO3352B1 (ar) * | 2005-06-17 | 2019-03-13 | Apr Applied Pharma Res Sa | صيغ دايكلوفيناك وطرق استخدامه |
US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
CA2615063A1 (fr) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | Formes posologiques et preparations a charge medicamenteuse elevee |
US20070036859A1 (en) * | 2005-08-11 | 2007-02-15 | Perry Ronald L | Sustained release antihistamine and decongestant composition |
CN101360485B (zh) * | 2005-10-26 | 2013-04-17 | 班纳制药公司 | 作为胶囊填充物的基于亲水性载体的双重控释基质系统 |
GB0525461D0 (en) | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
KR20090010953A (ko) * | 2006-03-28 | 2009-01-30 | 자블린 파머슈티칼스 인코포레이티드 | 저 복용량의 비-스테로이드성 항염증성 약물 및 베타-사이클로덱스트린 제형 |
KR20170123724A (ko) * | 2006-03-28 | 2017-11-08 | 자블린 파머슈티칼스 인코포레이티드 | 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
EP2046119A2 (fr) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Traitement de troubles psychiatriques |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
AU2007338631A1 (en) * | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
NZ579972A (en) * | 2007-05-24 | 2012-03-30 | Novartis Ag | Oral dosage form of diclofenac providing fast absorption of drug |
US7662858B2 (en) * | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
KR101096429B1 (ko) * | 2008-07-18 | 2011-12-20 | 한국유나이티드제약 주식회사 | 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제 |
RU2537137C2 (ru) * | 2009-11-09 | 2014-12-27 | Ксенопорт, Инк. | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения |
KR101346750B1 (ko) * | 2010-06-07 | 2013-12-31 | 한국콜마주식회사 | 나프록센 액상 조성물을 함유하는 밀봉된 경질캡슐제 |
GB201021267D0 (en) * | 2010-12-15 | 2011-01-26 | Reckitt Benckiser Healthcare Int Ltd | Novel pharmaceutical formulation |
EP2736519B1 (fr) * | 2011-07-27 | 2022-04-13 | B Athanassiadis Dental Pty Ltd | Compositions alcalines et leur utilisation dentaire et médicale |
WO2013058996A1 (fr) | 2011-10-19 | 2013-04-25 | R.P. Scherer Technologies, Llc | Système d'administration pharmaceutique à deux phases |
US20150250751A1 (en) | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
US20150250750A1 (en) | 2012-10-16 | 2015-09-10 | Wockhardt Limited | Pharmaceutical compostions of diclofenac or salts thereof |
US20150238451A1 (en) | 2012-10-19 | 2015-08-27 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
ES2792682T3 (es) | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
PT3104853T (pt) | 2014-02-10 | 2020-01-14 | Respivant Sciences Gmbh | Tratamento com estabilizadores de mastócitos para distúrbios sistémicos |
RU2743347C2 (ru) | 2014-10-21 | 2021-02-17 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
EP3331522A1 (fr) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Méthodes de traitement de troubles liés aux mastocytes par des stabilisateurs de mastocytes |
CA3035528A1 (fr) | 2016-08-31 | 2018-03-08 | Respivant Sciences Gmbh | Compositions de cromolyne pour le traitement de la toux chronique due a une fibrose pulmonaire idiopathique |
CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
IT201700015145A1 (it) * | 2017-02-10 | 2018-08-10 | Altergon Sa | Capsule di gelatina molle ad elevata stabilità |
GB2585628A (en) * | 2019-05-08 | 2021-01-20 | Alkaloid Ad | Pharmaceutical formulation |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
WO2023235541A1 (fr) * | 2022-06-03 | 2023-12-07 | Polaryx Therapeutics, Inc. | Formulation de gemfibrozil |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4028772A (en) | 1971-04-02 | 1973-09-27 | Merck & Co., Inc | Chemical processes |
HU185926B (en) | 1979-09-27 | 1985-04-28 | Agostne Kahan | Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives |
US5071643A (en) * | 1986-10-17 | 1991-12-10 | R. P. Scherer Corporation | Solvent system enhancing the solubility of pharmaceuticals for encapsulation |
US4880835A (en) | 1988-11-03 | 1989-11-14 | Formulations Development Labs, Inc. | Oral liquid pharmaceutical compositions of sulindac |
JPH0717498B2 (ja) * | 1989-05-31 | 1995-03-01 | 興和株式会社 | 鎮咳去痰ソフトカプセル剤 |
CA2017916C (fr) | 1989-06-07 | 1999-02-02 | Minoru Aoki | Preparations a base d'etoposide |
US5024997A (en) * | 1990-06-22 | 1991-06-18 | American Home Products Corporation | Palatable ibuprofen solutions |
US5141961A (en) * | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
US5183829A (en) * | 1991-09-27 | 1993-02-02 | Applied Analytical Industries, Inc. | Oral liquid compositions of non-steroidal anti-inflammatory drugs |
DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
US5505961A (en) | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
NZ279443A (en) * | 1994-01-24 | 1998-04-27 | Procter & Gamble | Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol |
ES2088742B1 (es) * | 1994-06-29 | 1997-03-16 | Salvat Lab Sa | Composicion antibiotica de aplicacion otica. |
CA2141126A1 (fr) * | 1995-01-26 | 1996-07-27 | Natalie J. Lazarowych | Medicament d'association pour le traitement de la migraine et d'autres affections |
US5616621A (en) * | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
US5641512A (en) * | 1995-03-29 | 1997-06-24 | The Procter & Gamble Company | Soft gelatin capsule compositions |
US5516789A (en) * | 1995-04-12 | 1996-05-14 | Abbott Laboratories | Lipoxygenase and cyclooxygenase inhibiting compounds |
US6013280A (en) | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
IT1295369B1 (it) * | 1997-10-21 | 1999-05-12 | Fatro Spa | Composizione a base di tiamfenicolo e diclofenac |
US6287594B1 (en) * | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
-
1999
- 1999-07-16 US US09/354,982 patent/US6365180B1/en not_active Expired - Lifetime
-
2000
- 2000-07-14 KR KR1020027000568A patent/KR20020050223A/ko not_active Application Discontinuation
- 2000-07-14 BR BR0012488-5A patent/BR0012488A/pt not_active Application Discontinuation
- 2000-07-14 WO PCT/US2000/019372 patent/WO2001013897A1/fr not_active Application Discontinuation
- 2000-07-14 JP JP2001518035A patent/JP2003507415A/ja active Pending
- 2000-07-14 EP EP00948703A patent/EP1196147A4/fr not_active Withdrawn
- 2000-07-14 UA UA2002010408A patent/UA80085C2/uk unknown
- 2000-07-14 SK SK57-2002A patent/SK572002A3/sk not_active Application Discontinuation
- 2000-07-14 MX MXPA02000583A patent/MXPA02000583A/es active IP Right Grant
- 2000-07-14 RU RU2002103873/15A patent/RU2252019C2/ru not_active IP Right Cessation
- 2000-07-14 CA CA002376180A patent/CA2376180A1/fr not_active Abandoned
- 2000-07-14 AU AU62168/00A patent/AU770772B2/en not_active Ceased
- 2000-07-14 CN CN00812537A patent/CN1407887A/zh active Pending
- 2000-07-14 SI SI200020031A patent/SI20849A/sl unknown
- 2000-07-14 CZ CZ2002129A patent/CZ2002129A3/cs unknown
-
2002
- 2002-01-15 NO NO20020208A patent/NO20020208L/no not_active Application Discontinuation
- 2002-01-17 HR HR20020045A patent/HRP20020045A2/xx not_active Application Discontinuation
- 2002-01-28 ZA ZA200200741A patent/ZA200200741B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20020050223A (ko) | 2002-06-26 |
RU2252019C2 (ru) | 2005-05-20 |
NO20020208D0 (no) | 2002-01-15 |
US6365180B1 (en) | 2002-04-02 |
CZ2002129A3 (cs) | 2002-08-14 |
WO2001013897A1 (fr) | 2001-03-01 |
MXPA02000583A (es) | 2003-10-14 |
BR0012488A (pt) | 2002-04-02 |
AU6216800A (en) | 2001-03-19 |
EP1196147A1 (fr) | 2002-04-17 |
SI20849A (sl) | 2002-10-31 |
UA80085C2 (en) | 2007-08-27 |
CN1407887A (zh) | 2003-04-02 |
AU770772B2 (en) | 2004-03-04 |
SK572002A3 (en) | 2002-08-06 |
EP1196147A4 (fr) | 2005-04-20 |
NO20020208L (no) | 2002-03-18 |
CA2376180A1 (fr) | 2001-03-01 |
ZA200200741B (en) | 2003-06-25 |
JP2003507415A (ja) | 2003-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020045A2 (en) | Oral liquid compositions | |
ATE429210T1 (de) | Orale flüssige zusammensetzungen | |
DE3688114D1 (de) | Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate. | |
BRPI9917007B8 (pt) | azabicicloalcanos como moduladores de ccr5, composição farmacêutica contendo os mesmos, bem como seu uso | |
NO20030897L (no) | Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer | |
BR9906920A (pt) | "tts contendo um antioxidante" | |
DE69940674D1 (de) | Orale verabreichung von adenosin analogen | |
HUP0302474A2 (hu) | Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
BR0314898A (pt) | Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica | |
NO912888L (no) | Fremgangsmaate for fremstilling av nye peperidylethere og -thioethere. | |
ATE215817T1 (de) | Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis | |
FR2717081B1 (fr) | Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro. | |
ATE346592T1 (de) | Pharmazeutische zubereitungen mit einem cortisol synthese inhibitor | |
ATE13488T1 (de) | Gallium-chlorid, ein neues antikrebsmittel. | |
BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
ATE347886T1 (de) | Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen | |
ATE256134T1 (de) | Sulfatierte phosphatidylinositole, ihre herstellung und verwendung | |
DE69800210D1 (de) | Wasserfreies Mittel auf Lactulosebasis | |
ES2165727T3 (es) | Composiciones de administracion por via oral con baja dosificacion de proteinas citotoxicas. | |
MEP39708A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine | |
BR0009113A (pt) | Composição farmacêutica à base de compostospoliaromáticos | |
UA39044A (uk) | Склад для лікування хвороб пародонта | |
FR2833945A1 (fr) | N-cyclopropylmethyl-azacycloalcanes, compositions les contenant et procedes de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20050609 Year of fee payment: 6 |
|
A1OB | Publication of a patent application | ||
OBST | Application withdrawn |